Translating mighty mice into neuromuscular therapeutics: is bigger muscle better?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Drug discovery and development for rare genetic disorders.American journal of medical genetics. Part A · 2017
   Review
2. Deletion of connexin43 in osteoblasts/osteocytes leads to impaired muscle formation in mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015
   Article
3. S1P lyase in skeletal muscle regeneration and satellite cell activation: exposing the hidden lyase.Biochimica et biophysica acta · 2013
   Review
4. High-content drug screening with engineered musculoskeletal tissues.Tissue engineering. Part B, Reviews · 2010
   Review

Corrections and comments

• Comment on
  Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy.2006

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as